Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Optimizing systemic therapy and sequencing for stage I TNBC

Marleen Kok • 23 Oct 2026
ESMO 2026
Breast Cancer

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the management of stage I triple negative breast cancer (TNBC), highlighting the lack of clinical trials and data on the benefit of chemotherapy for this specific disease stage. Dr Kok notes that the prognosis for patients with stage I TNBC is generally good, and therefore, it is essential to identify patients with indolent biology who may not require chemotherapy, and explores the potential of biomarkers such as tumor-infiltrating lymphocytes (TILs) to inform treatment decisions. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marleen Kok

Optimizing immunotherapy for triple-negative breast cancer
0:47
Optimizing immunotherapy for triple-negative breast cancer
Marleen Kok • 13 Mar 2025
Assessing who can benefit from immunotherapy in ER+ breast cancer
1:13
Assessing who can benefit from immunotherapy in ER+ breast cancer
Marleen Kok • 13 Mar 2025
Reaching a consensus on early TNBC treatment guidelines
1:32
Reaching a consensus on early TNBC treatment guidelines
Marleen Kok • 13 Mar 2025
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
1:08
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
Marleen Kok • 16 Mar 2023

Related Videos

Treating triple negative early breast cancer after optimal neoadjuvant therapy
2:24
Treating triple negative early breast cancer after optimal neoadjuvant therapy
Joana Ribeiro • 25 Oct 2026
POP-DURVA: short-term preoperative durvalumab in stage I TNBC
1:20
POP-DURVA: short-term preoperative durvalumab in stage I TNBC
Joana Ribeiro • 25 Oct 2026
OPT-PEMBRO: adjuvant pembrolizumab de-escalation in early TNBC
1:30
OPT-PEMBRO: adjuvant pembrolizumab de-escalation in early TNBC
Joana Ribeiro • 25 Oct 2026
VEGF and immunotherapy combinations in breast and lung cancer
1:26
VEGF and immunotherapy combinations in breast and lung cancer
Alessandra Curioni-Fontecedro • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals